{
  "method": "HypoGeniC",
  "study_context": {
    "dataset": "accord",
    "treatment": "Intensive glucose control (HbA1c target <6.0%)",
    "outcome": "Major cardiovascular events (nonfatal MI, nonfatal stroke, cardiovascular death)",
    "population": "Adults with type 2 diabetes and high cardiovascular risk",
    "sample_size": 200,
    "method": "HypoGeniC"
  },
  "algorithm_parameters": {
    "num_init": 30,
    "top_k": 15,
    "w_max": 100,
    "max_iterations": 5
  },
  "hypotheses": [
    {
      "hypothesis": {
        "hypothesis_id": "H1",
        "title": "Older Age and Intensive Glucose Control",
        "hypothesis_statement": "Older adults (age >= 65) experience more harm than benefit from intensive glucose control for cardiovascular events.",
        "treatment_recommendation": {
          "subgroup_rule": {
            "feature": "baseline_age",
            "operator": ">=",
            "threshold": 65.0,
            "category": null,
            "description": "Patients who are 65 years or older"
          },
          "recommendation": "control",
          "expected_benefit": "harm",
          "rationale": "Older adults may have increased susceptibility to hypoglycemia, which can precipitate cardiovascular events."
        },
        "mechanism": "Age-related decline in glucose counter-regulation mechanisms increases hypoglycemia risk.",
        "evidence_basis": [
          "Previous studies showing age-related hypoglycemia sensitivity"
        ],
        "testable_prediction": "Within the study population, patients aged 65 or older receiving intensive glucose control will have higher rates of major cardiovascular events compared to standard treatment."
      },
      "reward": 55.0,
      "correct_predictions": 107,
      "total_predictions": 200
    },
    {
      "hypothesis": {
        "hypothesis_id": "H5",
        "title": "Baseline Hypertension and Glucose Control",
        "hypothesis_statement": "Patients with high baseline systolic blood pressure (SBP > 140) benefit less from intensive glucose control for cardiovascular event prevention.",
        "treatment_recommendation": {
          "subgroup_rule": {
            "feature": "sbp",
            "operator": ">",
            "threshold": 140.0,
            "category": null,
            "description": "Patients with baseline SBP greater than 140 mmHg"
          },
          "recommendation": "control",
          "expected_benefit": "low",
          "rationale": "High baseline SBP may lead to increased cardiovascular risk, overshadowing glucose control benefits."
        },
        "mechanism": "Chronic hypertension could lead to vascular damage, reducing glucose control effectiveness.",
        "evidence_basis": [
          "Meta-analyses associating high SBP with modulated glucose control benefits"
        ],
        "testable_prediction": "Patients with SBP > 140 will not see a significant reduction in cardiovascular events with intensive glucose control compared to standard management."
      },
      "reward": 55.0,
      "correct_predictions": 107,
      "total_predictions": 200
    },
    {
      "hypothesis": {
        "hypothesis_id": "H6",
        "title": "Previous Cardiovascular Disease and Glucose Control",
        "hypothesis_statement": "Patients with a history of cardiovascular disease (CVD) benefit less from intensive glucose control compared to those without.",
        "treatment_recommendation": {
          "subgroup_rule": {
            "feature": "cvd_hx_baseline",
            "operator": "==",
            "threshold": null,
            "category": "yes",
            "description": "Patients with a history of cardiovascular disease at baseline"
          },
          "recommendation": "control",
          "expected_benefit": "low",
          "rationale": "Existing cardiovascular damage may limit the potential benefits from improved glucose control."
        },
        "mechanism": "Pre-existing atherosclerotic disease limits regeneration of cardiovascular health through glucose reduction.",
        "evidence_basis": [
          "Studies showing attenuated cardiovascular benefits in patients with prior events"
        ],
        "testable_prediction": "Patients with a baseline history of CVD have similar cardiovascular event rates regardless of glucose control intensity."
      },
      "reward": 55.0,
      "correct_predictions": 107,
      "total_predictions": 200
    },
    {
      "hypothesis": {
        "hypothesis_id": "H2",
        "title": "High Baseline BMI and Cardiovascular Outcomes",
        "hypothesis_statement": "Patients with high baseline BMI (>30) benefit more from intensive glucose control in terms of reducing major cardiovascular events.",
        "treatment_recommendation": {
          "subgroup_rule": {
            "feature": "bmi",
            "operator": ">",
            "threshold": 30.0,
            "category": null,
            "description": "Patients with BMI greater than 30"
          },
          "recommendation": "treat",
          "expected_benefit": "high",
          "rationale": "Obesity-related metabolic disturbances are more reversible with intensive glucose control."
        },
        "mechanism": "High baseline BMI is associated with increased insulin resistance and cardiovascular risk, which intensive glucose control can mitigate.",
        "evidence_basis": [
          "Studies indicating improved risk profiles in obese patients with aggressive treatment"
        ],
        "testable_prediction": "Patients with BMI >30 under intensive glucose control will have fewer cardiovascular events than those under standard care."
      },
      "reward": 36.0,
      "correct_predictions": 93,
      "total_predictions": 200
    },
    {
      "hypothesis": {
        "hypothesis_id": "H3",
        "title": "Low HDL Cholesterol and Intensive Glucose Control",
        "hypothesis_statement": "Patients with low HDL levels (<40 mg/dL) experience reduced benefits from intensive glucose control compared to standard care.",
        "treatment_recommendation": {
          "subgroup_rule": {
            "feature": "hdl",
            "operator": "<",
            "threshold": 40.0,
            "category": null,
            "description": "Patients with HDL cholesterol less than 40 mg/dL"
          },
          "recommendation": "control",
          "expected_benefit": "low",
          "rationale": "Low HDL may indicate an increased risk for unpredictable cardiovascular complications not mitigated by glucose control alone."
        },
        "mechanism": "Low HDL is often associated with persistent cardiovascular risk that glucose control cannot sufficiently alter.",
        "evidence_basis": [
          "Epidemiological studies linking low HDL with reduced cardiovascular benefit from glucose control"
        ],
        "testable_prediction": "Lower HDL levels (<40 mg/dL) correlate with a lesser reduction in cardiovascular events under intensive glucose management."
      },
      "reward": 36.0,
      "correct_predictions": 93,
      "total_predictions": 200
    },
    {
      "hypothesis": {
        "hypothesis_id": "H4",
        "title": "Renal Function and Glucose Control",
        "hypothesis_statement": "Patients with reduced renal function (GFR < 60) show more harm from intensive glucose control in preventing cardiovascular events.",
        "treatment_recommendation": {
          "subgroup_rule": {
            "feature": "gfr",
            "operator": "<",
            "threshold": 60.0,
            "category": null,
            "description": "Patients with GFR less than 60"
          },
          "recommendation": "control",
          "expected_benefit": "harm",
          "rationale": "Reduced renal function may lead to increased accumulation of glucose-lowering agents, raising hypoglycemia risk."
        },
        "mechanism": "Impaired renal function affects drug clearance, increasing risk of toxic metabolites or side effects.",
        "evidence_basis": [
          "Clinical observations of increased hypoglycemia in patients with chronic kidney disease"
        ],
        "testable_prediction": "Patients with GFR < 60 will experience a higher incidence of adverse cardiovascular outcomes on intensive glucose control."
      },
      "reward": 36.0,
      "correct_predictions": 93,
      "total_predictions": 200
    }
  ],
  "summary": {
    "total_hypotheses": 6,
    "avg_reward": 45.5,
    "avg_accuracy": 0.49999999999999994
  }
}